A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 347-357

  Maresca, K P ^a   Hillier, S M ^a   Femia, F J ^a   Keith, D ^a   Barone, C ^a   Joyal, J L ^a   Zimmerman, C N ^a   Kozikowski, A P ^b   Barrett, J A ^a   Eckelman, W C ^a   Babich, J W ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [1 CARBOXY 5 (4 IODOBENZYLAMINO)PENTYL]UREIDO]PENTANEDIOIC ACID I 123; 2 [3 [1 CARBOXY 5 [3 (4 IODOPHENYL)UREIDO]PENTYL]UREIDO]PENTANEDIOIC ACID I 123; ASCORBIC ACID; GENTISIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMIC ACID; HALIDE; HETERODIMER; IODINE 123; IODINE 131; LYSINE; MOLECULAR MARKER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UREA; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; HALOGEN; MEMBRANE ANTIGEN;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG FORMULATION; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; PROSTATE CANCER; RADIOASSAY; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE TUMOR; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTIGENS, SURFACE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; GLUTAMATE CARBOXYPEPTIDASE II; HALOGENS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS; RADIOLIGAND ASSAY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 60549117368     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800994j     Document Type: Article

References (36)

1. American Cancer Society Cancer Statistics, SEER data 2008.
2. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M. J. Cancer statistics. Ca-Cancer J. Clin. 2003, 53, 5-26.
3. Lapidus, R. G.; Tiffany, C. W.; Isaacs, J. T.; Slusher, B. S. Prostate- specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000, 45, 350-354.
4. Pinto, J. T.; Suffoletto, B. P.; Bergin, T. M.; Quaio, C. H.; Lin, S.; Tong, W. P.; May, F.; Mukherjee, B.; Heston, W. D. W. Prostate specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 1996, 2, 1445-1451.
5. Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Navarro, V.; Hunter, C. J.; Bastidas, D.; Bander, N. H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000, 60, 5237-5243.
6. Ross, J. S.; Sheehan, C. E.; Fisher, H. A., Jr.; Kaur, P.; Gray, K.; Webb, I.; Gray, G. S.; Mosher, R.; Kallakury, B. V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9, 6357-6362.
7. Tasch, J.; Gong, M.; Sadelain, M.; Heston, W. D. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy. Crit. Rev. Immunol. 2001, 21, 249-261.
8. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D.; Olson, W. C. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12590-12595.
9. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor associated neovasculature. Cancer Res. 1999, 59, 3192-3198.
10. Murphy, G. P.; Elgamal, A. A.; Su, S. L.; Bostwick, D. G.; Holmes, E. H. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998, S3, 2259-2269.
11. Smith-Jones, P. M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S. J.; Bander, N. H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 2003, 44, 610-617.
12. Friedrich, S. W.; Lin, S. C.; Stoll, B. R.; Baxter, L. T.; Munn, L. L.; Jain, R. K. Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 2002, 4, 449-463.
13. Maloney, D. G.; Grillo-Lopez, A. J.; Bodkin, D.; White, C. A.; Liles, T.-M; Royston, I.; Varns, C.; Rosenberg, J.; Levy, R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non Hodgkin's lymphoma. J. Clin. Oncol. 1997, 15, 3266-3274.
14. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990, 50 (3, Suppl.), 814s-819s.
15. Scher, B.; Seitz, M.; Albinger, W.; Tiling, R.; Scherr, M.; Becker, H. C.; Souvatzogluou, M.; Gildehaus, F. J.; Westerv, H. J.; Dresel, S. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 45-53.
16. 11C]-choline positron-emission/ computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007, 100, 786-793.
17. 11C-choline PET/CT. J. Nucl. Med. 2006, 47, 1249-1254.
18. 11C-choline the most appropriate tracer for prostate cancer? Against. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 756-759.
19. 11C acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007, 99, 1415-1420.
20. Stoermer, D.; Liu, Q.; Hall, M. R.; Flanary, J. M.; Thomas, A. G.; Rojas, C. R.; Slusher, B. S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-based inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett. 2003, 13, 2097-2100.
21. Speno, H. S.; Luthi-Carter, R.; Macias, W. L.; Valentine, S. L.; Joshi, A. R.; Coyle, J. T. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Moipmrmacol. 1999, 55, 179-185.
22. Nan, F.; Bzdega, T.; Pshenichkin, S.; Wroblewski, J. T.; Wroblewska, B.; Neale, J. H.; Kozikowski, A. P. Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J. Med. Chem. 2000, 43, 772-774.
23. Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J. H.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NALADase). J. Med. Chem. 2001, 44, 298-301.
24. Barinka, C.; Hlouchova, K.; Rovenska, M.; Majer, P.; Dauter, M.; Hin, N.; Ko, Y.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J. Mol. Biol. 2008, 376, 1438-1450.
25. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J.Med.Chem. 2007, 50, 3267-3273.
26. Barinka, C.; Rinnova, M.; Sacha, P.; Rojas, C.; Majer, P.; Slusher, B.S.; Konvalinka, J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J. Neurochem 2002, 80, 477-487.
27. Wang, X.; Yin, L.; Rao, P.; Stein, R.; Harsch, K. M.; Lee, Z.; Heston, W. D. W. Targeted treatment of prostate cancer. J. Cell. Biochem 2007, 702, 571-579.
28. Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 2005, 11, 4022-402.
29. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol. Imaging 2002, 1, 96-101.
30. 125I. J. Radioanal. Nucl. Chem. 1996, 206, 155-163.
31. Babich, J. W.; Eckelman, W. C. Applications of nuclear imaging in drug discovery and development. Drug Discovery Div. 2006, 1, 365-381.
32. Chen, W.; Botvinick, E. H.; Alavi, A.; Zhang, Y.; Yang, S.; Perini, R.; Zhuang, H. Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I -123 metaiodobenzylguanidine imaging. J. Nucl. Cardiol. 2008, 15, 73-79.
33. Fullerton, N. E.; Boyd, M.; Ross, S. C.; Pimlott, S. L.; Babich, J.; Kirk, D.; Zalutsky, M. R.; Mairs, R. J. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med. Chem. 2005, 1, 611-618.
34. Flux, G. D.; Guy, M. J.; Papavasileiou, P.; South, C.; Chittenden, S. J.; Flower, M. A.; Meller, S. T. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother. Radiopharm. 2003, 18, 81-87.
35. 125I labeled iodobenzodiazepines. Appl. Radiat. Isot. 1991, 42, 173-175.
36. 211At- ]MABG. J. Labelled Compd. Radiopharm. 2007, 50, 177-182.